vs

Side-by-side financial comparison of Clarus Corp (CLAR) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $65.4M, roughly 1.1× Clarus Corp). Clarus Corp runs the higher net margin — -47.8% vs -121.9%, a 74.1% gap on every dollar of revenue. On growth, Health Catalyst, Inc. posted the faster year-over-year revenue change (-6.2% vs -8.4%). Clarus Corp produced more free cash flow last quarter ($11.6M vs $9.6M). Over the past eight quarters, Health Catalyst, Inc.'s revenue compounded faster (-0.0% CAGR vs -2.9%).

Clarus Corp is a global designer, manufacturer, and distributor of high-performance outdoor recreation, climbing, camping, and lifestyle products. It manages a portfolio of leading consumer brands, serving outdoor enthusiasts, professional athletes, and retail partners across North America, Europe, and the Asia-Pacific region, with a focus on innovative, durable gear for active lifestyles.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

CLAR vs HCAT — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.1× larger
HCAT
$74.7M
$65.4M
CLAR
Growing faster (revenue YoY)
HCAT
HCAT
+2.2% gap
HCAT
-6.2%
-8.4%
CLAR
Higher net margin
CLAR
CLAR
74.1% more per $
CLAR
-47.8%
-121.9%
HCAT
More free cash flow
CLAR
CLAR
$1.9M more FCF
CLAR
$11.6M
$9.6M
HCAT
Faster 2-yr revenue CAGR
HCAT
HCAT
Annualised
HCAT
-0.0%
-2.9%
CLAR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLAR
CLAR
HCAT
HCAT
Revenue
$65.4M
$74.7M
Net Profit
$-31.3M
$-91.0M
Gross Margin
27.7%
Operating Margin
-59.6%
-115.3%
Net Margin
-47.8%
-121.9%
Revenue YoY
-8.4%
-6.2%
Net Profit YoY
52.3%
-340.3%
EPS (diluted)
$-0.81
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLAR
CLAR
HCAT
HCAT
Q4 25
$65.4M
$74.7M
Q3 25
$69.3M
$76.3M
Q2 25
$55.2M
$80.7M
Q1 25
$60.4M
$79.4M
Q4 24
$71.4M
$79.6M
Q3 24
$67.1M
$76.4M
Q2 24
$56.5M
$75.9M
Q1 24
$69.3M
$74.7M
Net Profit
CLAR
CLAR
HCAT
HCAT
Q4 25
$-31.3M
$-91.0M
Q3 25
$-1.6M
$-22.2M
Q2 25
$-8.4M
$-41.0M
Q1 25
$-5.2M
$-23.7M
Q4 24
$-65.5M
$-20.7M
Q3 24
$-3.2M
$-14.7M
Q2 24
$-5.5M
$-13.5M
Q1 24
$21.9M
$-20.6M
Gross Margin
CLAR
CLAR
HCAT
HCAT
Q4 25
27.7%
Q3 25
35.1%
52.6%
Q2 25
35.6%
Q1 25
34.4%
Q4 24
33.4%
Q3 24
35.0%
47.5%
Q2 24
36.1%
Q1 24
35.9%
Operating Margin
CLAR
CLAR
HCAT
HCAT
Q4 25
-59.6%
-115.3%
Q3 25
-4.4%
-22.9%
Q2 25
-19.7%
-46.0%
Q1 25
-11.2%
-25.4%
Q4 24
-70.2%
-22.0%
Q3 24
-8.0%
-17.9%
Q2 24
-14.4%
-20.8%
Q1 24
-9.8%
-30.5%
Net Margin
CLAR
CLAR
HCAT
HCAT
Q4 25
-47.8%
-121.9%
Q3 25
-2.3%
-29.1%
Q2 25
-15.3%
-50.8%
Q1 25
-8.7%
-29.9%
Q4 24
-91.8%
-26.0%
Q3 24
-4.7%
-19.3%
Q2 24
-9.7%
-17.8%
Q1 24
31.6%
-27.6%
EPS (diluted)
CLAR
CLAR
HCAT
HCAT
Q4 25
$-0.81
$-1.29
Q3 25
$-0.04
$-0.32
Q2 25
$-0.22
$-0.59
Q1 25
$-0.14
$-0.35
Q4 24
$-1.72
$-0.33
Q3 24
$-0.08
$-0.24
Q2 24
$-0.14
$-0.23
Q1 24
$0.57
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLAR
CLAR
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$36.7M
$95.7M
Total DebtLower is stronger
$0
$153.3M
Stockholders' EquityBook value
$196.4M
$245.8M
Total Assets
$249.0M
$502.6M
Debt / EquityLower = less leverage
0.00×
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLAR
CLAR
HCAT
HCAT
Q4 25
$36.7M
$95.7M
Q3 25
$29.5M
$91.5M
Q2 25
$28.5M
$97.3M
Q1 25
$41.3M
$342.0M
Q4 24
$45.4M
$392.0M
Q3 24
$36.4M
$387.3M
Q2 24
$46.2M
$308.3M
Q1 24
$47.5M
$327.8M
Total Debt
CLAR
CLAR
HCAT
HCAT
Q4 25
$0
$153.3M
Q3 25
$2.0M
$153.1M
Q2 25
$1.9M
$153.0M
Q1 25
$1.9M
$382.9M
Q4 24
$1.9M
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
$37.0K
Stockholders' Equity
CLAR
CLAR
HCAT
HCAT
Q4 25
$196.4M
$245.8M
Q3 25
$225.8M
$331.9M
Q2 25
$225.1M
$347.5M
Q1 25
$229.3M
$376.8M
Q4 24
$233.1M
$365.2M
Q3 24
$308.5M
$355.0M
Q2 24
$307.3M
$357.0M
Q1 24
$310.4M
$357.2M
Total Assets
CLAR
CLAR
HCAT
HCAT
Q4 25
$249.0M
$502.6M
Q3 25
$283.1M
$587.1M
Q2 25
$286.5M
$616.2M
Q1 25
$292.8M
$891.5M
Q4 24
$294.1M
$858.9M
Q3 24
$375.3M
$813.0M
Q2 24
$369.4M
$691.7M
Q1 24
$377.0M
$695.1M
Debt / Equity
CLAR
CLAR
HCAT
HCAT
Q4 25
0.00×
0.62×
Q3 25
0.01×
0.46×
Q2 25
0.01×
0.44×
Q1 25
0.01×
1.02×
Q4 24
0.01×
1.05×
Q3 24
0.97×
Q2 24
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLAR
CLAR
HCAT
HCAT
Operating Cash FlowLast quarter
$12.5M
$9.9M
Free Cash FlowOCF − Capex
$11.6M
$9.6M
FCF MarginFCF / Revenue
17.7%
12.9%
Capex IntensityCapex / Revenue
1.4%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-9.9M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLAR
CLAR
HCAT
HCAT
Q4 25
$12.5M
$9.9M
Q3 25
$-5.7M
$-464.0K
Q2 25
$-9.4M
$-9.0M
Q1 25
$-2.1M
$280.0K
Q4 24
$16.6M
$-3.5M
Q3 24
$-8.3M
$6.2M
Q2 24
$834.0K
$1.6M
Q1 24
$-16.4M
$10.3M
Free Cash Flow
CLAR
CLAR
HCAT
HCAT
Q4 25
$11.6M
$9.6M
Q3 25
$-7.0M
$-719.0K
Q2 25
$-11.3M
$-9.2M
Q1 25
$-3.3M
$-390.0K
Q4 24
$14.4M
$-3.9M
Q3 24
$-9.4M
$5.5M
Q2 24
$-744.0K
$1.3M
Q1 24
$-18.3M
$10.1M
FCF Margin
CLAR
CLAR
HCAT
HCAT
Q4 25
17.7%
12.9%
Q3 25
-10.0%
-0.9%
Q2 25
-20.4%
-11.4%
Q1 25
-5.4%
-0.5%
Q4 24
20.1%
-4.9%
Q3 24
-14.0%
7.2%
Q2 24
-1.3%
1.7%
Q1 24
-26.3%
13.5%
Capex Intensity
CLAR
CLAR
HCAT
HCAT
Q4 25
1.4%
0.4%
Q3 25
1.8%
0.3%
Q2 25
3.4%
0.3%
Q1 25
2.0%
0.8%
Q4 24
3.1%
0.5%
Q3 24
1.6%
0.9%
Q2 24
2.8%
0.4%
Q1 24
2.7%
0.3%
Cash Conversion
CLAR
CLAR
HCAT
HCAT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-0.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLAR
CLAR

Other$37.1M57%
Outdoor Segment$25.3M39%
Adventure Segment$3.0M5%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons